In the Realm of Chemistry, asymmetric synthesis has a prime importance as it allows creation of optically pure chemical entities. The synthesis of preferred enantiomer is highly desirable when seeking for specific biological activities owing to the importance of chirality. AsymmFlow delineates synthesis, characterization and application of novel asymmetric supported organocatalysts for enantioselective Pictet-Splengler cyclization in continuous flow/batch to produce tetrahydro-β-carboline (THβC) derivatives. The proposed immobilization strategy gives access to synthesize reusable, robust and stable catalytic systems for asymmetric continuous-flow processes. We aim to develop a sustainable and selective protocol which would give easy access to bioactive substituted-THβC moieties and thus fulfils the demand aiming at lowering their prices in global markets. In particular, the synthesis of the drug Tadalafil usually suffers for poor enantioselectivity, prolonged reaction times, and scale-up issues. It is expected that the development of an alternative protocol for the synthesis of Taladafil will solve those common synthetic challenges and thus, will be highly useful to bring down the market price of this drug all over the world.
Fellow name: Moreshwar Chaudhari